• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Alpha Healthcare Acquisition Corp. III

    11/15/23 4:56:30 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care
    Get the next $ALPA alert in real time by email
    NT 10-Q 1 d942135dnt10q.htm NT 10-Q NT 10-Q

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 12b-25

     

     

    Commission File Number: 000-56468

    NOTIFICATION OF LATE FILING

     

     

    ☐  Form 10-K     ☐  Form 20-F     ☐  Form 11-K     ☒  Form 10-Q    

    ☐  Form 10-D     ☐  Form N-SAR

      For Period Ended: September 30, 2023
      ☐  Transition Report on Form 10-K
      ☐  Transition Report on Form 20-F
      ☐  Transition Report on Form 11-k
      ☐  Transition Report on Form 10-Q
      ☐  Transition Report on Form N-SAR
      For the Transition Period Ended:                     

     

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

     

     

    PART I – REGISTRANT INFORMATION

    Carmell Corporation

    Full name of registrant

     

    Former name if applicable

    2403 Sidney Street, Suite 300

    Address of principal executive office

    Pittsburgh, Pennsylvania 15203

    City, state and zip code

    PART II – RULE 12b-25 (b) AND (c)

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

        (a)   The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
     
    ☒       (b)   The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
     
        (c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

    PART III – NARRATIVE

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report, or portion thereof, could not be filed within the prescribed time period.

    Carmell Corporation (the “Company”) was not able to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Quarterly Report”) within the prescribed time period without unreasonable effort due to a software issue related to XBRL tagging that was resolved and led to the Quarterly Report being with the Securities and Exchange Commission (the “SEC”) at 5:58 pm eastern time, shortly after the filing deadline of 5:30 pm eastern time. The Quarterly Report has been filed and is currently available on the SEC’s EDGAR website.

    PART IV – OTHER INFORMATION

     

    (1)          Name and telephone number of person to contact in regard to this notification
        Bryan J. Cassaday          (281)          297-8276
        (Name)     (Area Code)     (Telephone Number)
    (2)     Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).     ☒  Yes    ☐  No
            
    (3)     Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?     ☒  Yes    ☐  No
        If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

    The Company’s results of operations for the three and nine months ended September 30, 2023 reflect the completion of a material acquisition in August 2023. As the Quarterly Report has been filed prior to this Form 12b-25 report, please see the Quarterly Report for more detailed information.

    Safe Harbor for Forward-Looking Statements

    Information in this Form 12b-25 report regarding the Company’s expected results and other expectations and beliefs that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All forward-looking statements included in this report are based upon information available to the Company as of the date of this report, which may change, and the Company assumes no obligation to update any such forward-looking statements.

     

     

    Carmell Corporation

    (Name of Registrant as Specified in Charter)

    has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

     

    Dated:   

    November 15, 2023

        By:     

    /s/ Bryan J. Cassaday

             

    Bryan J. Cassaday

             

    Chief Financial Officer

     

     

     

    Get the next $ALPA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALPA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ALPA
    SEC Filings

    View All

    Alpha Healthcare Acquisition Corp. III filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Carmell Corp (0001842939) (Filer)

    1/16/24 7:27:40 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Alpha Healthcare Acquisition Corp. III filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Carmell Corp (0001842939) (Filer)

    1/16/24 7:14:47 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Alpha Healthcare Acquisition Corp. III filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Carmell Corp (0001842939) (Filer)

    1/16/24 7:07:47 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    $ALPA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Shukla Rajiv was granted 14,347 shares and acquired 0 shares, increasing direct ownership by 42% to 48,526 units (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    1/4/24 9:17:09 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Cassaday Bryan J. bought $1,540 worth of shares (440 units at $3.50), increasing direct ownership by 29% to 1,940 units (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    12/19/23 5:00:05 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Spenlehauer Gilles bought $3,456 worth of shares (904 units at $3.82) (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    12/18/23 5:13:12 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    $ALPA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Cassaday Bryan J. bought $1,540 worth of shares (440 units at $3.50), increasing direct ownership by 29% to 1,940 units (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    12/19/23 5:00:05 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Spenlehauer Gilles bought $3,456 worth of shares (904 units at $3.82) (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    12/18/23 5:13:12 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Frisch Scott M. bought $3,456 worth of shares (904 units at $3.82) (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    12/18/23 5:12:55 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    $ALPA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alpha Healthcare Acquisition Corp. III Announces Successful Closing of Business Combination with Carmell Therapeutics Corporation

    Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA) ("ALPA"), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the successful completion of its business combination (the "Business Combination") with Carmell Therapeutics Corporation, a Phase 2 stage regenerative medicine platform company developing allogeneic plasma-based biomaterials for active soft tissue repair, aesthetics and orthopedic indications ("Carmell"). The resulting combined company, Carmell Therapeutics Corporation, is expected to commence trading of its shares of common stock and warrants on the Nasdaq Capital Market® under the ticker symbols "CTCX" and "CTCXW," respectively, on July 17, 2023.

    7/14/23 3:12:00 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Alpha Healthcare Acquisition Corp. III Announces Non-Binding Letter of Intent to Acquire a Commercial Stage Regenerative Medicine Company Conditioned Upon Closing of Carmell Business Combination

    Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA) ("ALPA"), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the execution of a non-binding letter of intent (the "LOI") to acquire a commercial stage regenerative medicine company (the "Target") conditioned upon the closing of ALPA's initial business combination with Carmell Therapeutics Corporation, a Phase 2 stage regenerative medicine platform company developing allogeneic plasma-based biomaterials for active soft tissue repair, aesthetics and orthopedic indications ("Carmell"). ALPA has set a Stockholders Meeting (the "Meeting") to consider the previously announced business combination with Carmell for J

    6/27/23 7:00:00 AM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Alpha Healthcare Acquisition Corp. III Announces Merger with Carmell Therapeutics, a Phase 2 Stage Biotechnology Platform Company Developing Allogeneic Plasma-based Biomaterials for Bone and Soft Tissue Healing Indications

    Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA) ("ALPA"), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the execution of a definitive business combination agreement with Carmell Therapeutics Corporation ("Carmell™"), a Phase 2-stage biotechnology platform company developing allogeneic plasma-based biomaterials for bone and soft tissue healing indications. Upon closing of the transaction, ALPA will be renamed Carmell Therapeutics Corporation (the "Combined Company"). Mr. Shukla will serve as Chairman and Mr. Randy Hubbell will serve as Chief Executive Officer of the Combined Company. The Combined Company's common stock is expected to be listed on the Na

    1/4/23 10:11:00 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    $ALPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    2/14/24 4:13:13 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    2/14/24 3:42:33 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Alpha Healthcare Acquisition Corp. III

    SC 13G - Carmell Corp (0001842939) (Subject)

    2/14/24 12:54:27 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care